Comparison of Effects of Atorvastatin Versus Rosuvastatin on Cardiac Function in Heart Failure Patients
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
Statins have a protective effect in patients with established heart failure because of their
lipid-lowering and pleiotropic effects. There is no randomized controlled trial comparing
lipophilic versus hydrophilic statins in these patients (head to head comparison). The best
evidence so far is from a meta-analysis in which the authors did an adjusted indirect
comparison between lipophilic statins and rosuvastatin and found that lipophilic statins were
associated with significantly lower incidence of all-cause mortality, cardiovascular
mortality, and hospitalization for worsening heart failure compared to rosuvastatin
(hydrophilic statin) among patients with heart failure. So, the investigators plan to conduct
a randomized controlled trial comparing the effects of atorvastatin and rosuvastatin on
cardiac function in patients with heart failure with reduced ejection fraction.
Phase:
Phase 4
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research